(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052932 A3

(51) International Patent Classification[7]: C07K 16/18, C12N 15/13, 15/85, 5/10, A61K 39/395

(21) International Application Number: PCT/EP2003/013960

(22) International Filing Date: 9 December 2003 (09.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0228832.2 10 December 2002 (10.12.2002) GB

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant *(for all designated States except US)*: **UNIVERSITÄT ZÜRICH** [CH/CH]; Prorektorat Forschung, Rämistrasse 71, CH-8006 Zürich (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BARSKE, Carmen** [DE/DE]; Birkenweg 10, 79540 Loerrach (DE). **MIR, Anis, Khusro** [GB/FR]; Rue des Vosges 6, F-68870 Bartenheim (FR). **OERTLE, Thomas** [CH/CH]; Casa al lago, CH-6576 Gerra/Gambarogno (CH). **SCHNELL, Lisa** [CH/CH]; Schwanengasse 9, CH-8001 Zürich (CH). **SCHWAB, Martin, E.** [CH/CH]; Waffenplatz Strasse 79, CH-8002 Zürich (CH). **VITALITI, Alessandra** [CH/CH]; 6981 Bedigliora, CH- (CH). **ZURINI, Mauro** [CH/CH]; Benkenstrasse 92a, CH-4102 Binningen (CH).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report: 21 October 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTIBODY ("11C7") ANTI NOGO A AND ITS PHARMACEUTICAL USE

(57) Abstract: This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant < 1000nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair; a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.

WO 2004/052932 A3